Sociedad Americana de Hirudoterapia

Deciphering the role of the electrostatic interactions involving Gly70 in eglin C by total chemical protein synthesis

Structural biology study published in Biochemistry (2000)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Farmacología salivalLu WY et al. · Biochemistry, 2000

Abstract

Eglin c from the leech Hirudo medicinalis is a potent protein inhibitor of many serine proteinases including chymotrypsin and subtilisins. Unlike most small protein inhibitors whose solvent-exposed enzyme-binding loop is stabilized primarily by disulfide bridges flanking the reactive-site peptide bond, eglin c possesses an enzyme-binding loop supported predominantly by extensive electrostatic/H-bonding interactions involving three Arg residues (Arg48, Arg51, and Arg53) projecting from the scaffold of the inhibitor. As an adjacent residue, the C-terminal Gly70 participates in these interactions via its alpha-carboxyl group interacting with the side chain of Arg51 and the main chain of Arg48. In addition, the amide NH group of Gly70 donates an H-bond to the carbonyl C=O groups of Arg48 and Arg51. To understand the structural and functional relevance of the electrostatic/H-bonding network, we chemically synthesized wild-type eglin c and three analogues in which Gly70 was either deleted or replaced by glycine amide (NH(2)CH(2)CONH(2)) or by alpha-hydroxylacetamide (HOCH(2)CONH(2)). NMR analysis indicated that the core structure of eglin c was maintained in the analogues, but that the binding loop was significantly perturbed. It was found that deletion or replacement of Gly70 destabilized eglin c by an average of 2.7 kcal/mol or 20 degrees C in melting temperature. As a result, these inhibitors become substrates for their target enzymes. Binding assays on these analogues with a catalytically incompetent subtilisin BPN' mutant indicated that loss or weakening of the interactions involving the carboxylate of Gly70 caused a decrease in binding by approximately 2 orders of magnitude. Notably, for all four synthetic inhibitors, the relative free energy changes (DeltaDeltaG) associated with protein destabilization are strongly correlated (slope = 0.94, r(2) = 0. 9996) with the DeltaDeltaG values derived from a decreased binding to the enzyme.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsBinding SitesChymotrypsinGlycineKineticsLeechesMolecular Sequence DataNuclear Magnetic Resonance, BiomolecularProtein DenaturationProteinsSerpins

Resumen

Total chemical protein synthesis of eglin C variants probing the role of Gly70 in electrostatic interactions — reveals fold-stability determinants.

Por qué esto importa para la hirudoterapia

Esta investigación empleó la síntesis química total de proteínas para comprender el papel estructural del Gly70 en el eglin c, un potente inhibidor de serina proteinasas de la sanguijuela medicinal (Hirudo medicinalis). El estudio demostró que el Gly70 es crucial para la estabilidad estructural y la afinidad de unión del inhibidor, gracias a su participación en una red electrostática y de enlaces de hidrógeno. La comprensión de esta dinámica estructural es valiosa para los miembros de ASH interesados en la ingeniería fundamental de proteínas y en la estabilidad de los biofármacos derivados de sanguijuela. La matización es que se trata de un estudio biofísico in vitro altamente especializado, centrado exclusivamente en la estructura y la cinética de la proteína, sin ninguna aplicación directa en hirudoterapia clínica ni en organismos completos.

Citación

Deciphering the role of the electrostatic interactions involving Gly70 in eglin C by total chemical protein synthesis.

Lu WY et al. · Biochemistry, 2000

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.